Initial data from a pair of clinical trials may revive interest in arthritis drugs as COVID-19 treatments

Initial data from a pair of clinical trials may revive interest in arthritis drugs as COVID-19 treatments

There is some renewed hope for rheumatoid arthritis drugs like Eli Lilly’s Olumiant and Roche’s Actemra as possible COVID-19 treatments after a series of clinical setbacks this summer seemed to close the door on the category’s potential.

Read More…

You May Also Like